BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

TissueGene, Inc. Initiates Phase I Clinical Trial With TG-C


7/24/2006 10:34:34 AM

GAITHERSBURG, Md., July 24 /PRNewswire/ -- TissueGene, Inc., a privately- held biopharmaceutical company advancing a pipeline of promising regenerative medicine therapeutics, announced today the acceptance of the Company's Investigational New Drug application (IND), and for the initiation of its Phase I clinical trial evaluating a single dose of TG-C for the treatment of degenerative joint diseases. This clinical trial is designed to assess the safety of TG-C in patients who have opted for total knee arthroplasty.

TissueGene has developed TG-C to regenerate cartilage in patients suffering from degenerative arthritis and more specifically for indications such as osteoarthritis of the knee. As an alternative to other methods of cartilage repair, TG-C will involve minimally invasive injections versus a surgical approach. Other techniques currently involve multiple and often invasive surgical procedures and have mixed results.

"We are pleased with the approval to start our Phase I program with TG-C and feel that our drug candidate has the potential to be not first-in-class, but also best-in-class," stated Dr. K.H. Lee, President, founder and Chief Executive Officer of TissueGene.

About TissueGene:

TissueGene, Inc. is a privately-held biopharmaceutical company developing a pipeline of promising regenerative medicine therapeutics in the field of cell-mediated therapy, and has several related products in development for the treatment of degenerative diseases. TissueGene is focused on harnessing the power of well known, safe and effective growth factors combined with the dynamic regenerative capacity of mammalian cells to develop state of the art therapeutics.

For additional information on the company please visit http://www.tissuegene.com .

TissueGene, Inc.

CONTACT: J. Kelly Ganjei, Vice President of Business Development ofTissueGene, Inc., +1-301-921-6002, contact@tissuegene.com



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES